Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Have been diagnosed with Type 2 Diabetes on diet and exercise and/or a stable dose of metformin~* Have a stable body weight for the 3 months prior to randomization~* Have a body mass index (BMI) ≥23 kilogram/square meter (kg/m²)~* Males must agree to use highly effective methods of contraception~* Women not of childbearing potential (WNOCBP) may participate in this trial~* Note: Hormone replacement therapy in post-menopausal women is allowed but women must be on stable therapy for 3 months prior to day 1.~Exclusion Criteria:~* Have Type 1 diabetes mellitus (T1DM) or history of ketoacidosis or hyperosmolar coma~* Have a history of diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy that requires immediate treatment intervention~* Have had more than 1 episode of severe hypoglycemia and aware of hypoglycemic symptoms~* Have acute or chronic pancreatitis~* Have obesity induced other endocrine disorders (Cushing's syndrome or Prader - Willi syndrome)~* Have gastric emptying abnormality or chronically take medications impacting GI motility~* Have poorly controlled hypertension~* Have the following heart conditions within the last 6 months: myocardial infarction (MI), unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack (TIA), cerebrovascular accident (stroke)or decompensated congestive heart failure, or IV heart failure~* Have any symptoms of other liver diseases besides nonalcoholic fatty liver disease (NAFLD)~* Have HIV, or Hepatitis B or Hepatitis C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 3 milligrams (mg) LY3502970 (Type: EXPERIMENTAL): Participants received maintenance dose of 3 mg with dose escalation starting from 2 mg LY3502970 administered orally once daily (QD).
- 12 mg LY3502970 (Type: EXPERIMENTAL): Participants received maintenance dose 12 mg with dose escalation starting from 2 mg, 6 mg and then 12 mg LY3502970 administered orally QD.
- 24 mg LY3502970 (Type: EXPERIMENTAL): Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally QD.
- 36 mg LY3502970 - 1 (Type: EXPERIMENTAL): Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
- 36 mg LY3502970 - 2 (Type: EXPERIMENTAL): Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
- 45 mg LY3502970 - 1 (Type: EXPERIMENTAL): Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
- 45 mg LY3502970 - 2 (Type: EXPERIMENTAL): Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
- 1.5 mg Dulaglutide (Type: ACTIVE_COMPARATOR): Participants received 1.5 mg Dulaglutide administered subcutaneously (SC) once weekly (QW).
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).